Compare RGLD & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGLD | NBIX |
|---|---|---|
| Founded | 1981 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 14.4B |
| IPO Year | N/A | 1996 |
| Metric | RGLD | NBIX |
|---|---|---|
| Price | $209.32 | $155.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 19 |
| Target Price | ★ $213.38 | $174.84 |
| AVG Volume (30 Days) | 726.8K | ★ 924.1K |
| Earning Date | 11-05-2025 | 10-28-2025 |
| Dividend Yield | ★ 0.86% | N/A |
| EPS Growth | ★ 66.97 | 12.44 |
| EPS | ★ 7.28 | 4.19 |
| Revenue | $849,255,000.00 | ★ $2,682,700,000.00 |
| Revenue This Year | $25.73 | $23.76 |
| Revenue Next Year | $64.70 | $18.01 |
| P/E Ratio | ★ $28.77 | $37.13 |
| Revenue Growth | ★ 28.17 | 19.61 |
| 52 Week Low | $130.67 | $84.23 |
| 52 Week High | $209.43 | $160.18 |
| Indicator | RGLD | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 66.72 | 62.66 |
| Support Level | $198.14 | $150.26 |
| Resistance Level | $207.66 | $160.18 |
| Average True Range (ATR) | 5.69 | 4.25 |
| MACD | 1.21 | 0.76 |
| Stochastic Oscillator | 98.87 | 74.77 |
Royal Gold Inc enquires and manages precious metal royalties and streams with a focus on gold. The company purchases a percentage of the metal produced from a mineral property for an initial payment without assuming responsibility for mining operations. Similarly, precious metal streams are purchase agreements with mine operators providing the right to purchase all or a portion of one or more metals produced from a mine in exchange for an upfront deposit payment. Generally, Royal Gold does not work on the properties in which it holds royalty and streaming assets. The company owns a portfolio of producing, development, evaluation, and exploration royalties and streams, and the majority of group revenue is generated from Canada, Mexico, Chile, and the United States.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.